Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas

Journal of Neuro-Oncology

Volumn 87, Issue 2, 2008, Pages 181-187

  Guillevin, Remy ^a,e   Menuel, Carole ^a   Duffau, Hugues ^b,e   Kujas, Michel ^a   Capelle, Laurent ^a,e   Aubert, Agnès ^c   Taillibert, Sophie ^d   Idbaih, Ahmed ^d   Pallud, Joan ^c   Demarco, Giovanni ^d   Costalat, Robert ^a   Hoang Xuan, Khê ^d   Chiras, Jacques ^a   Vallée, Jean Noel ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c INSERM   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UPMC Univ Paris 06   (France)

Author keywords

KI 67 labeling index; Low grade glioma; Magnetic resonance spectroscopy

Indexed keywords

KI 67 ANTIGEN; LACTIC ACID; LIPID; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURGERY; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; GLIOMA; HEMISPHERE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; RELIABILITY; TUMOR BIOPSY; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BRAIN NEOPLASMS; CELL PROLIFERATION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS;

EID: 41549159456     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9508-y     Document Type: Article

References (47)

1. Alger JR et al (1990) Metabolism of human gliomas: Assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 177(3):633-641
2. Ott D, Hennig J, Ernst T (1993) Human brain tumors: Assessment with in vivo proton MR spectroscopy. Radiology 186(3):745-752
3. Michaelis T et al (1993) Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra. Radiology 187(1):219-227
4. Miller BL (1991) A review of chemical issues in 1H NMR spectroscopy: N-acetyl-l-aspartate, creatine and choline. NMR Biomed 4(2):47-52
5. Urenjak J et al (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13(3):981-989
6. Kemp GJ (2000) Non-invasive methods for studying brain energy metabolism: What they show and what it means. Dev Neurosci 22(5-6):418-428
7. Croteau D et al (2001) Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: Semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 49(4):823-829
8. Dowling C et al (2001) Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 22(4):604-612
9. Vuori K et al (2004) Low-grade gliomas and focal cortical developmental malformations: Differentiation with proton MR spectroscopy. Radiology 230(3):703-708
10. Herminghaus S et al (2003) Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 98(1):74-81
11. Yang D et al (2002) Cerebral gliomas: Prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44(8):656-666
12. Mandonnet E et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53(4):524-528
13. Hoyt JW et al (1995) Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24(2):163-169
14. Steck K, el-Naggar AK (1994) Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms. Cytometry 17(3):258-265
15. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88(12):2887
16. Czernicki Z et al (2000) Malignancy of brain tumors evaluated by proton magnetic resonance spectroscopy (1H-MRS) in vitro. Acta Neurochir Suppl 76:17-20
17. Isobe T et al (2002) Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 20(4):343-349
18. Tedeschi G et al (1997) Increased choline signal coinciding with malignant degeneration of cerebral gliomas: A serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87(4):516-524
19. Piepmeier JM (2001) Cerebral gliomas: How tumor biology affects management. Clin Neurosurg 48:3-9
20. Pallud J et al (2006) Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 60(3):380-383
21. Piepmeier J et al (1996) Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38(5):872-878 (discussion 878-879)
22. Louis DN et al (1991) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study. Acta Neuropathol (Berl) 81(6):675-679
23. Neder L et al (2004) MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol 23(6):262-270
24. Wakimoto H et al (1996) Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77(2):373-380
25. Daumas-Duport C et al (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62(10):2152-2165
26. Kondziolka D, Lunsford LD, Martinez AJ (1993) Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 79(4):533-536
27. Cao Y et al (2006) Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 24(8):1228-1235
28. Julia-Sape M et al (2006) Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg 105(1):6-14
29. Lev MH et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 25(2):214-221
30. Rees J (2003) Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 16(6):643-650
31. Onda K et al (1994) Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74(7):1921-1926
32. Matsumura A et al (2005) Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study. J Clin Neurosci 12(4):416-420
33. Shimizu H et al (2000) Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. Am J Neuroradiol 21(4):659-665
34. Law M et al (2006) Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58(6):1099-1107 (discussion 1099-1107)
35. Cha S et al (2003) Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. Magn Reson Med 49(5):848-855
36. Shin JH et al (2002) Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: Preliminary results. Am J Roentgenol 179(3):783-789
37. Sugahara T et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. Am J Roentgenol 171(6):1479-1486
38. Castillo M, Kwock L, Mukherji SK (1996) Clinical applications of proton MR spectroscopy. Am J Neuroradiol 17(1):1-15
39. Danielsen ER, Ross B (1999) Magnetic resonance spectroscopy diagnosis of neurological diseases (Book). Marcel Dekker, INC. Editor, New York, Basel
40. Leclerc X, Huisman TA, Sorensen AG (2002) The potential of proton magnetic resonance spectroscopy ((1)H-MRS) in the diagnosis and management of patients with brain tumors. Curr Opin Oncol 14(3):292-298
41. Nafe R et al (2003) Preoperative proton-MR spectroscopy of gliomas - correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol 63(3):233-245
42. Law M et al (2003) Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24(10):1989-1998
43. Reijneveld JC et al (2005) Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas. Neuroradiology 47(12):887-891
44. Duffau H et al (2005) Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: A comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 76(6):845-851
45. Hoang-Xuan K et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133-3138
46. Van den Bent MJ et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21(13):2525-2528
47. Van den Bent MJ (2003) Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol 30(6 suppl 19):39-44